Skeletal Effect of Semaglutide and Tirzepatide in Patients with Increased Risk of Fractures
Access to this document is restricted. Some items have been embargoed at the request of the author, but will be made publicly available after the "No Access Until" date.
During the embargo period, you may request access to the item by clicking the link to the restricted file(s) and completing the request form. If we have contact information for a Cornell author, we will contact the author and request permission to provide access. If we do not have contact information for a Cornell author, or the author denies or does not respond to our inquiry, we will not be able to provide access. For more information, review our policies for restricted content.
CONTEXT: Glucagon-like peptide-1 receptor agonists (GLP1-RA) have potent glucose-lowering and weight loss benefits, but their effects on bone remain unclear. OBJECTIVE: To investigate changes in bone mineral density (BMD) in patients using semaglutide (SEM) and tirzepatide (TIR), a dual agonist of GLP-1/glucose dependent insulinotropic polypeptide. METHODS: Single-center retrospective study. Adult patients using SEM/TIR for ≥6 months with DXA scans before initiation and at least 6 months after were matched by age, sex, BMI, and diabetes mellitus (DM) to non-users with at least two DXA scans over the same period. The primary outcome was percentage change in total hip (TH) BMD. RESULTS: We included 255 patients using SEM or TIR in the GLP-1 RA group (92% female, mean age 64±9 years, BMI 31.0±5.6 kg/m²) and 255 controls. After a median follow-up of 17 months, the GLP-1 RA group achieved median 5% weight loss. Both groups had significant declines in BMD at TH and FN, with similar magnitude between groups. In the GLP-1RA group, weight loss was directly associated with bone loss at the TH and FN (r=0.32 for TH, r=0.17 for FN, both p<0.01). Among patients without DM, greater TH bone loss was noted in GLP-1 RA group compared to controls (-1% vs -0.6%, p=0.04), whereas TH bone loss was similar between groups among patients with DM. CONCLUSION: SEM/TIR use was associated with greater annualized TH bone loss in patients without DM, whereas TH bone loss was comparable between GLP-1 RA and controls in patients with DM. These findings suggest GLP-1 RA's effects on bone may differ by DM status, with weight loss driving bone loss in patients without DM.